Search Medical Condition
Please enter condition
Please choose location from dropdown

Tobacco Use Disorder Clinical Trials

A listing of Tobacco Use Disorder medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (164) clinical trials

Wake Research Associates in Raleigh, is looking for moist smokeless tobacco users to participate in a research study. If you have used a pouch or loose cut smokeless tobacco for at least 12 months, you may be eligible to join this study looking at how nicotine absorbs in the blood ...

Phase N/A

Behavioral Activation and Varenicline for Smoking Cessation in Depressed Smokers

Upwards of 43% of persons with major depressive disorder (MDD) are daily smokers who are more likely to smoke heavily, show greater tobacco dependence, suffer more severe withdrawal, and experience lower quit rates than smokers without MDD. Little is known about treatment strategies that might optimize smoking cessation for smokers ...

Phase

Examination of Low Wattage and High Wattage E-Cigarettes

The overall aim of the proposed study is to evaluate the effect of switching from conventional cigarettes to either a LWe or HWe on smoking behavior, product use patterns and continued use, as well as biomarkers of toxicant exposure and effects.

Phase N/A

Optimizing Smoking Cessation for People With HIV/AIDS Who Smoke

We propose a factorial design strategy to evaluate the effects, individually and in combination, of the most promising pharmaco- and behavioral cessation therapies available for PLWH according to our review of the extant literature for HIV-infected and general population smokers. The sizable cohort and prospective design will also permit us ...

Phase

Menthol Flavored E-cigarette Use During a Simulated Ban of Menthol Cigarettes

The purpose of this formative study is to provide preliminary data regarding how the availability of menthol flavored e-cigarettes affects tobacco use behavior in the context of a ban on menthol flavored cigarettes

Phase N/A

Effect of Banning Menthol Flavorant on Cigarette and E-Cigarette Use

In this pilot study, menthol cigarette smokers will be randomized to one of three experimental marketplaces: 1) a condition simulating a ban on menthol cigarettes but not menthol e-cigarettes (condition A); 2) a condition simulating a ban on both menthol cigarettes and menthol e-cigarettes (Condition B); and 3) a condition ...

Phase N/A

Abuse Liability of Reduced Nicotine Content Cigarettes Within a Complex Tobacco Marketplace

Tobacco regulatory policies can have unanticipated consequences; therefore, methods that would permit prospective estimates of the effects of potential tobacco regulations are necessary for the development of tobacco regulatory science. The goal of this project is to experimentally assess how smokers purchase and consume reduced-nicotine cigarettes. In experiment 1, we ...

Phase N/A

Effect of Cigarette Pack Warnings and Packaging Among Young Adult Smokers

The study includes young adult smokers ages 18 to 30. Eligible participants are young adults ages 18 to 30 years inclusive who report smoking at least 100 lifetime cigarettes and now smoking on all or some days. Participants must also reside in the metro Washington, DC area. The first portion ...

Phase N/A

Testing an Organizational Change Model to Address Smoking in Mental Healthcare

Despite an overall reduction in US smoking rates from >50% in the 1960s to about 20% by 2000, the rate of smoking among persons with a serious mental illness (SMI) remains 2-3 times greater than in the general population. Transforming the mental healthcare system to integrate and adhere to evidence-based ...

Phase N/A

Neural Mechanisms Associated With Risk of Smoking Relapse

Smoking is the greatest preventable cause of mortality and a significant economic burden. Even with the best available treatments, most smokers relapse within days or weeks after a quit attempt. Nicotine replacement therapy, the most widely used pharmacotherapy, yields end of treatment quit rates of <25% suggesting that managing nicotine ...

Phase N/A